Recommendations for the pharmacological treatment of COPD: questions and answers
Nenhuma Miniatura disponível
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
SOC BRASILEIRA PNEUMOLOGIA TISIOLOGIA
Autores
CAMELIER, Aquiles Assuncao
FRITSCHER, Carlos Cezar
COSTA, Claudia Henrique da
PEREIRA, Eanes Delgado Barros
GODOY, Irma
CANCADO, Jose Eduardo Delfini
ROMALDINI, Jose Gustavo
CHATKIN, Jose Miguel
Citação
JORNAL BRASILEIRO DE PNEUMOLOGIA, v.43, n.4, p.290-301, 2017
Resumo
O tratamento da DPOC vem se tornando cada vez mais eficaz. Medidas que envolvem desde mudanças comportamentais, redução de exposições a fatores de risco, educação sobre a doença e seu curso, reabilitação, oxigenoterapia, manejo de comorbidades, tratamentos cirúrgicos e farmacológicos até os cuidados de fim de vida permitem ao profissional oferecer uma terapêutica personalizada e efetiva. O tratamento farmacológico da DPOC constitui um dos principais pilares desse manejo, e muitos avanços têm sido atingidos na área nos últimos anos. Com a maior disponibilidade de medicações e combinações terapêuticas fica cada vez mais desafiador conhecer as indicações, limitações, potenciais riscos e benefícios de cada tratamento. Com o intuito de avaliar criticamente a evidência recente e sistematizar as principais dúvidas referentes ao tratamento farmacológico da DPOC, foram reunidos 24 especialistas de todo o Brasil para elaborar a presente recomendação. Foi elaborado um guia visual para a classificação e tratamento adaptados à nossa realidade. Dez perguntas foram selecionadas pela relevância na prática clínica. Abordam a classificação, definições, tratamento e evidências disponíveis para cada medicação ou combinação. Cada pergunta foi respondida por dois especialistas e depois consolidadas em duas fases: revisão e consenso entre todos os participantes. As questões respondidas são dúvidas práticas e ajudam a selecionar qual o melhor tratamento, entre as muitas opções, para cada paciente com suas particularidades.
The treatment of COPD has become increasingly effective. Measures that range from behavioral changes, reduction in exposure to risk factors, education about the disease and its course, rehabilitation, oxygen therapy, management of comorbidities, and surgical and pharmacological treatments to end-of-life care allow health professionals to provide a personalized and effective therapy. The pharmacological treatment of COPD is one of the cornerstones of COPD management, and there have been many advances in this area in recent years. Given the greater availability of drugs and therapeutic combinations, it has become increasingly challenging to know the indications for, limitations of, and potential risks and benefits of each treatment modality. In order to critically evaluate recent evidence and systematize the major questions regarding the pharmacological treatment of COPD, 24 specialists from all over Brazil gathered to develop the present recommendations. A visual guide was developed for the classification and treatment of COPD, both of which were adapted to fit the situation in Brazil. Ten questions were selected on the basis of their relevance in clinical practice. They address the classification, definitions, treatment, and evidence available for each drug or drug combination. Each question was answered by two specialists, and then the answers were consolidated in two phases: review and consensus by all participants. The questions answered are practical questions and help select from among the many options the best treatment for each patient and his/her peculiarities.
The treatment of COPD has become increasingly effective. Measures that range from behavioral changes, reduction in exposure to risk factors, education about the disease and its course, rehabilitation, oxygen therapy, management of comorbidities, and surgical and pharmacological treatments to end-of-life care allow health professionals to provide a personalized and effective therapy. The pharmacological treatment of COPD is one of the cornerstones of COPD management, and there have been many advances in this area in recent years. Given the greater availability of drugs and therapeutic combinations, it has become increasingly challenging to know the indications for, limitations of, and potential risks and benefits of each treatment modality. In order to critically evaluate recent evidence and systematize the major questions regarding the pharmacological treatment of COPD, 24 specialists from all over Brazil gathered to develop the present recommendations. A visual guide was developed for the classification and treatment of COPD, both of which were adapted to fit the situation in Brazil. Ten questions were selected on the basis of their relevance in clinical practice. They address the classification, definitions, treatment, and evidence available for each drug or drug combination. Each question was answered by two specialists, and then the answers were consolidated in two phases: review and consensus by all participants. The questions answered are practical questions and help select from among the many options the best treatment for each patient and his/her peculiarities.
Palavras-chave
Doença pulmonar obstrutiva crônica/tratamento farmacológico, Doença pulmonar obstrutiva crônica/prevenção & controle, Doença pulmonar obstrutiva crônica/ terapia., Pulmonary disease, chronic obstructive/drug therapy, pulmonary disease, chronic obstructive/prevention & control, pulmonary disease, chronic obstructive/therapy
Referências
- Aaron SD, 2007, ANN INTERN MED, V146, P545
- Agusti A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-122
- Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623
- Almagro P, 2002, CHEST, V121, P1441, DOI 10.1378/chest.121.5.1441
- Andreeva-Gateva PA, 2016, POSTGRAD MED, V128, P474, DOI 10.1080/00325481.2016.1186487
- ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196
- Anzueto A, 2010, EUR RESPIR REV, V19, P113, DOI 10.1183/09059180.00002610
- Appleton S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001104.pub2
- Fernandes FLA, 2010, J BRAS PNEUMOL, V36, P181, DOI 10.1590/S1806-37132010000200005
- Menezes AMB, 2011, J BRAS PNEUMOL, V37, P527, DOI 10.1590/S1806-37132011000400016
- Barnes PJ, 2016, CHEST, V149, P7, DOI 10.1016/j.chest.2015.08.017
- Barr RG, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002876.pub2
- Bateman ED, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0250-2
- Bateman ED, 2013, EUR RESPIR J, V42, P1484, DOI 10.1183/09031936.00200212
- Bridevaux PO, 2008, THORAX, V63, P768, DOI 10.1136/thx.2007.093724
- Brusselle G, 2015, INT J CHRONIC OBSTR, V10, P2207, DOI 10.2147/COPD.S91694
- Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070
- Calverley PMA, 2009, LANCET, V374, P685, DOI 10.1016/S0140-6736(09)61255-1
- Casaburi Richard, 2014, Ann Am Thorac Soc, V11, P1351, DOI 10.1513/AnnalsATS.201404-174OC
- Cazzola M, 2015, EUR RESPIR REV, V24, P451, DOI 10.1183/16000617.00002215
- Celli BR, 2008, RESP MED, V102, pS27, DOI 10.1016/S0954-6111(08)70005-2
- Chong J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002309.pub4
- Crim Courtney, 2015, Ann Am Thorac Soc, V12, P27, DOI 10.1513/AnnalsATS.201409-413OC
- Dal Negro R, 2008, ADV THER, V25, P1019, DOI [10.1007/s12325-008-0105-2, 10.1007/s12325-008-0105-z]
- Decramer M, 2005, LANCET, V365, P1552, DOI 10.1016/S0140-6736(05)66456-2
- Decramer M, 2014, LANCET RESP MED, V2, P472, DOI 10.1016/S2213-2600(14)70065-7
- Decramer ML, 2013, LANCET RESP MED, V1, P524, DOI 10.1016/S2213-2600(13)70158-9
- Derom E, 2016, INT J CHRONIC OBSTR, V11, P3163, DOI 10.2147/COPD.S92840
- Domingo-Salvany A, 2002, AM J RESP CRIT CARE, V166, P680, DOI 10.1164/rccm.2112043
- Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847
- Donath E, 2013, RESP MED, V107, P1385, DOI 10.1016/j.rmed.2013.05.004
- Donohue JF, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-78
- Enright P, 2014, THORAX, V69, P401, DOI 10.1136/thoraxjnl-2013-203497
- Flume PA, 2016, J CYST FIBROS, V15, P495, DOI 10.1016/j.jcf.2015.12.004
- Fowdar K, 2017, HEART LUNG, V46, P120, DOI 10.1016/j.hrtlng.2016.12.004
- Ghobadi Hassan, 2012, Tanaffos, V11, P22
- Global Initiative for Chronic Obstructive Lung Disease, GLOB IN CHRON OBSTR
- Groenewegen KH, 2003, CHEST, V124, P459, DOI 10.1378/chest.124.2.459
- Halpin DMG, 2012, INT J CHRONIC OBSTR, V7, P653, DOI 10.2147/COPD.S34186
- Herath SC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009764.pub2
- HODGKIN JE, 1990, CLIN CHEST MED, V11, P555
- Tse HN, 2013, CHEST, V144, P106, DOI 10.1378/chest.12-2357
- Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883
- Incalzi RA, 1997, EUR RESPIR J, V10, P2794, DOI 10.1183/09031936.97.10122794
- Nannini LJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006826.pub2
- Johansson Gunnar, 2008, Prim Care Respir J, V17, P169, DOI 10.3132/pcrj.2008.00037
- Johnson K, 2016, INT J CHRONIC OBSTR, V11, P799, DOI 10.2147/COPD.S102375
- Jones PW, 2009, EUR RESPIR J, V34, P648, DOI 10.1183/09031936.00102509
- Jung KS, 2012, RESP MED, V106, P382, DOI 10.1016/j.rmed.2011.09.004
- Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542
- Kim S, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-35
- Magnussen H, 2014, NEW ENGL J MED, V371, P1285, DOI 10.1056/NEJMoa1407154
- Mahler DA, 2014, EUR RESPIR J, V43, P1599, DOI 10.1183/09031936.00124013
- Maraffi Tommaso, 2010, Ther Adv Respir Dis, V4, P135, DOI 10.1177/1753465810368552
- Martinez FJ, 2016, AM J RESP CRIT CARE, V194, P559, DOI 10.1164/rccm.201607-1349OC
- McAllister DA, 2012, EUR RESPIR J, V39, P1097, DOI 10.1183/09031936.00124811
- Miravitlles M, 2004, THORAX, V59, P387, DOI 10.1136/thx.2003.008730
- Miravitlles M, 2016, INT J CHRONIC OBSTR, V11, P2041, DOI 10.2147/COPD.S114566
- Miravitlles M, 2015, PULM PHARMACOL THER, V32, P119, DOI 10.1016/j.pupt.2014.05.002
- Miravitlles M, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0122-1
- Montuschi P, 2016, DRUG DISCOV TODAY, V21, P1820, DOI 10.1016/j.drudis.2016.07.009
- Nishimura K, 2002, CHEST, V121, P1434, DOI 10.1378/chest.121.5.1434
- O'Donnell DE, 2016, RESPIROLOGY, V21, P211, DOI 10.1111/resp.12619
- Oba Y, 2016, THORAX, V71, P15, DOI 10.1136/thoraxjnl-2014-206732
- Pascoe S, 2015, LANCET RESP MED, V3, P435, DOI 10.1016/S2213-2600(15)00106-X
- Pavord ID, 2016, THORAX, V71, P118, DOI 10.1136/thoraxjnl-2015-207021
- Rabe KF, 2005, LANCET, V366, P563, DOI 10.1016/S0140-6736(05)67100-0
- Reichert Jonatas, 2008, J. bras. pneumol., V34, P845, DOI 10.1590/S1806-37132008001000014
- Rodrigo GJ, 2012, PULM PHARMACOL THER, V25, P40, DOI 10.1016/j.pupt.2011.10.006
- Rodriguez-Roisin R, 2000, CHEST, V117, p398S, DOI 10.1378/chest.117.5_suppl_2.398S
- Sanguinetti CM, 2016, MULTIDISCIP RESP MED, V11, DOI 10.1186/s40248-016-0039-2
- Schols AMWJ, 1998, AM J RESP CRIT CARE, V157, P1791
- Seemungal TAR, 2008, AM J RESP CRIT CARE, V178, P1139, DOI 10.1164/rccm.200801-145OC
- Sethi S, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-10
- Short PM, 2012, CHEST, V141, P81, DOI 10.1378/chest.11-0038
- Siddiqui SH, 2015, AM J RESP CRIT CARE, V192, P523, DOI 10.1164/rccm.201502-0235LE
- Silva GE, 2004, CHEST, V126, P59, DOI 10.1378/chest.126.1.59
- Silva Guilherme Pinheiro Ferreira da, 2013, J Bras Pneumol, V39, P402, DOI 10.1590/S1806-37132013000400002
- Singh D, 2008, THORAX, V63, P592, DOI 10.1136/thx.2007.087213
- Singh D, 2016, LANCET, V388, P963
- Soler-Cataluna JJ, 2005, THORAX, V60, P925, DOI 10.1136/thx.2005.040527
- Spencer S, 2004, EUR RESPIR J, V23, P698, DOI 10.1183/09031936.04.00121404
- Suzuki T, 2001, CHEST, V120, P730, DOI 10.1378/chest.120.3.730
- Taegtmeyer AB, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13628
- Tse HN, 2014, INT J CHRONIC OBSTR, V9, P825, DOI 10.2147/COPD.S51057
- van Buul AR, 2017, EXPERT REV RESP MED, V11, P311, DOI 10.1080/17476348.2017.1305894
- Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3
- Vignola AM, 2004, RESP MED, V98, P495, DOI 10.1016/j.rmed.2003.12.012
- Vogelmeier CF, 2017, EUR RESPIR J, V49
- Watz H, 2016, LANCET RESP MED, V4, P390, DOI 10.1016/S2213-2600(16)00100-4
- Wedzicha JA, 2016, NEW ENGL J MED, V374, P2222, DOI 10.1056/NEJMoa1516385
- Wedzicha JA, 2016, INT J CHRONIC OBSTR, V11, P81, DOI 10.2147/COPD.S89849
- Wedzicha JA, 2013, LANCET RESP MED, V1, P199, DOI 10.1016/S2213-2600(13)70052-3
- Wedzicha JA, 2013, BMC MED, V11, DOI [10.1186/1741-7015-11-181, 10.1186/PREACCEPT-1257101657996810]
- Welte T, 2009, AM J RESP CRIT CARE, V180, P741, DOI 10.1164/rccm.200904-0492OC
- Wenzel RP, 2012, NEW ENGL J MED, V367, P340, DOI 10.1056/NEJMct1115170
- Wilson R, 2013, J INFECTION, V67, P497, DOI 10.1016/j.jinf.2013.08.010
- Wouters EFM, 2005, THORAX, V60, P480, DOI 10.1136/thx.2004.034280
- Yamaya M, 2012, EUR RESPIR J, V40, P485, DOI 10.1183/09031936.00208011
- Zheng JP, 2014, LANCET RESP MED, V2, P187, DOI 10.1016/S2213-2600(13)70286-8